CN112972354A - Skin care composition and application thereof in cosmetics - Google Patents
Skin care composition and application thereof in cosmetics Download PDFInfo
- Publication number
- CN112972354A CN112972354A CN202110216055.6A CN202110216055A CN112972354A CN 112972354 A CN112972354 A CN 112972354A CN 202110216055 A CN202110216055 A CN 202110216055A CN 112972354 A CN112972354 A CN 112972354A
- Authority
- CN
- China
- Prior art keywords
- extract
- skin
- skin care
- care composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000002537 cosmetic Substances 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 83
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 23
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 23
- 230000002829 reductive effect Effects 0.000 claims abstract description 13
- 239000004381 Choline salt Substances 0.000 claims abstract description 8
- 235000019417 choline salt Nutrition 0.000 claims abstract description 8
- 150000003248 quinolines Chemical class 0.000 claims abstract description 7
- 229940084750 sophora flavescens root extract Drugs 0.000 claims abstract description 7
- 241000219357 Cactaceae Species 0.000 claims abstract description 6
- 229930195210 Ophiopogon Natural products 0.000 claims abstract description 5
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 229940088598 enzyme Drugs 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000012071 phase Substances 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000000287 crude extract Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- RJRZRMYKFWYPNX-UHFFFAOYSA-N [NH4+].[NH4+].CCO.[O-]S([O-])(=O)=O Chemical compound [NH4+].[NH4+].CCO.[O-]S([O-])(=O)=O RJRZRMYKFWYPNX-UHFFFAOYSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 229940106157 cellulase Drugs 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 230000010355 oscillation Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 240000000073 Achillea millefolium Species 0.000 claims description 6
- 235000007754 Achillea millefolium Nutrition 0.000 claims description 6
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 6
- 108010059820 Polygalacturonase Proteins 0.000 claims description 5
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 241001078983 Tetradium ruticarpum Species 0.000 claims description 3
- -1 glycerol phosphoinositide choline salt Chemical class 0.000 claims description 3
- 239000004382 Amylase Substances 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000037307 sensitive skin Effects 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 7
- 230000001133 acceleration Effects 0.000 abstract description 4
- 230000003020 moisturizing effect Effects 0.000 abstract description 4
- 230000009759 skin aging Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 206010040830 Skin discomfort Diseases 0.000 abstract description 3
- 208000038016 acute inflammation Diseases 0.000 abstract description 3
- 230000006022 acute inflammation Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 208000037976 chronic inflammation Diseases 0.000 abstract description 3
- 230000006020 chronic inflammation Effects 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 60
- 230000000052 comparative effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000003266 anti-allergic effect Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 240000001439 Opuntia Species 0.000 description 5
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 5
- 210000003837 chick embryo Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000005191 phase separation Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 3
- 229940035437 1,3-propanediol Drugs 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102100037611 Lysophospholipase Human genes 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 150000002316 glycerophosphocholines Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940038580 oat bran Drugs 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000004727 Opuntia ficus indica Nutrition 0.000 description 1
- 240000009297 Opuntia ficus-indica Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of cosmetics, and particularly discloses a skin care composition which comprises the following active ingredients: beta-glucan, glycerophosphoinositide choline salt, an ophiopogon root extract, a twisted cactus stem extract and a sophora flavescens root extract. Compared with the prior art, the composition provided by the invention has the advantages that through the interaction among the components, namely the synergistic effect, on one hand, the moisture content of the skin is increased, the immunity of the skin is increased, on the other hand, the skin discomfort caused by acute inflammation is relieved, the skin aging acceleration caused by chronic inflammation is reduced, the skin is soft and comfortable, and the composition has good and long-term effects of moisturizing and relieving sensitive skin.
Description
Technical Field
The invention relates to the field of cosmetics, and particularly relates to a skin care composition and application thereof in cosmetics.
Background
With the acceleration of the rhythm of work and life, people are under greater pressure, the rule of diet work and rest is abnormal, the environment is polluted, and the health condition of skin is gradually reduced and becomes more sensitive. People pay more and more attention to how to relieve skin sensitivity, and the word 'sensitive muscle' is more and more deep into the heart.
Sensitive skin, also known as sensitive skin, refers to a highly reactive state of the skin under physiological or pathological conditions. Sensitive skin is a common problematic skin in a sub-health state, when the skin is stimulated by physical, chemical, mental and other factors, the skin is more prone to subjective symptoms such as burning, stabbing pain, pruritus and tightness, accompanied by objective signs such as poor erythema, scale, telangiectasia and the like, and is seriously prone to red swelling and rash, accompanied by vexation of uneven skin color, inflammation fading is easy to leave marks or spots, the female morbidity is higher than that of the male, and the recovery period is long and the skin is very easy to repeat.
The formation principle of sensitive muscles is that the natural defense system of the skin is in question, and thus the recruitment ability to external stimuli is lost. The first warning of a decrease in the natural defense function of the skin is the breakdown of the sebaceous membrane. The sebaceous membrane is a natural protective membrane of the skin and is formed by combining sebum secreted from sebaceous glands, lipids produced by keratinocytes and sweat secreted from sweat glands. The sebum membrane can protect skin moisture, has barrier effect, and can moisten skin; can prevent bacteria from invading externally, and has the functions of sterilization, bacteriostasis and infection resistance. Once the sebum membrane is damaged, not only the water retention function is reduced, the skin becomes dry and itchy, even desquamate, but also the defense force to cold, heat and touch pressure is weakened, and the phenomena of red swelling and local redness are easily caused. The sensitive skin is mainly focused on basic maintenance work such as moisture preservation and the like, the moisture content of the skin is increased, the barrier function of the skin is enhanced, the resistance of the skin can be greatly enhanced, and the stimulation of external substances to the skin is reduced.
Aiming at the sensitive skin group, a skin care product with the effect of relieving and repairing the sensitive skin appears on the market in order to reduce the abnormal phenomena of red swelling, itching, allergic dermatitis and the like of the skin caused by the stimulation of the skin by the cosmetics with adverse reactions. The product follows the principles of minimizing potential allergens, reducing irritation to skin, reconstructing skin barrier and the like, preferably selects natural soothing raw materials, such as centella, chamomile, honeysuckle and other natural plants, has the effects of diminishing inflammation, resisting oxidation, improving vascular rupture, improving the sensitivity of skin to cold and hot irritation and the like, and has relatively high safety.
However, currently, there are still few skin care products with soothing sensitive skin and there is very limited choice for consumers.
Disclosure of Invention
The invention aims to overcome at least one defect (deficiency) of the prior art and provides a skin care composition which can relieve irritation, improve skin immunity and is suitable for sensitive skin.
The invention also provides the application of the composition in cosmetics.
The invention adopts the technical scheme that the skin care composition comprises the following active ingredients: beta-glucan, glycerophosphoinositide choline salt, an ophiopogon root extract, a twisted cactus stem extract and a sophora flavescens root extract.
The beta-glucan promotes proliferation of Langerhans cells, improves skin immunity, promotes self-healing of the skin, improves wrinkles and improves elasticity; the choline glycerophosphoinositide inhibits a key enzyme of inflammatory reaction, namely cytosolic phospholipase A2(cPLA2), inhibits inflammatory mediators, and has anti-inflammatory and soothing effects; the radix ophiopogonis extract is rich in radix ophiopogonis polysaccharide, can be cooperated with other moisturizing functional components, relieves the symptom of allergic dermatitis, promotes the absorption of the moisturizing functional components, and improves sensitive skin; the prickly pear stem extract has good antioxidation, also has remarkable effects of high-efficiency water replenishing and radiation protection, ensures high nutrition, high purity and high activity of natural organic functional components, and can protect skin from ultraviolet radiation; the sophora flavescens root extract can reduce the release of an allergic medium histamine, has a good relieving effect on skin itch, and the plant Chinese herbal medicines can balance grease secretion, dredge and astringe pores, clear away toxin impurities in the skin, enrich the nutrition of the herbal medicines, promote the growth and repair of damaged vascular nerve cells, recover the activity of subcutaneous capillary cells, consolidate the self-defense of the skin and resist stimulation.
The composition provided by the invention is compounded by the synergistic effect of multiple components, and can relieve the skin discomfort caused by acute inflammation, reduce the skin aging acceleration caused by chronic inflammation and make the skin soft and comfortable by inhibiting inflammatory factors and improving the skin immunity.
As a preferred technical scheme, the skin care composition comprises the following components in parts by weight:
as a preferable technical scheme, the health-care food also comprises 3-20 parts of trehalose.
As a preferable technical scheme, the medicine also comprises 0.05-4 parts of fructus evodiae extract.
Evodia rutaecarpa has been used as a traditional Chinese medicinal material for thousands of years. The plant essence extracted from the fructus evodiae acts on the skin, improves microcirculation, promotes the nutrition and oxygen supply of skin cells, accelerates the metabolism of the skin and enables the skin to be ruddy, glossy and uniform.
As a preferred technical scheme, the fructus evodiae extract is mainly prepared by the following steps:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: (10-30) mL of the extract solution is added, the mixture is placed in a pressure-resistant bag and treated for 3-5 minutes under certain pressure, and a solution part is recovered, wherein the extraction solvent is one or more of water, propylene glycol and butanediol, and the pressure is 250-350 MPa;
s3: adding complex enzyme with the weight of 0.4-0.7% of the powder into the solution obtained in the step S2, and performing enzymolysis for 2-4h at 40-50 ℃; the complex enzyme is two or more of cellulase, pectinase, glucanase, xylanase and amylase;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: (10-20) mL of the extract is added into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirred, subjected to oscillation reaction for 1-2 hours at the temperature of 50-70 ℃, kept stand, subjected to phase splitting and then recovered into an upper phase extract;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
As a preferable technical scheme, the oat peptide food further comprises 1-40 parts of oat peptide.
Oat peptide is a small molecular peptide which is obtained by dissociating protein in oat bran into small molecules by using modern biotechnology, namely enzyme engineering, is very similar to Epidermal Growth Factor (EGF), is easy to absorb by skin, accelerates cell proliferation, promotes skin metabolism and activates the skin. According to the scheme, the oat peptide is added to be compounded with other components, so that the synergistic effect is realized, the metabolism of the skin is promoted, the cell proliferation is accelerated, the skin injury is prevented and repaired, and the skin aging caused by inflammation is resisted.
A preferable technical scheme is that the medicine also comprises 0.005-2 parts of the yarrow extract. The yarrow extract is added in the formula, so that the skin cell communication can be promoted, the skin thickness can be increased, the skin barrier can be enhanced, the skin immunity can be improved, and the problem of skin sensitivity can be fundamentally solved.
As a preferable technical scheme, the beta-glucan is one or more of oat beta-glucan and yeast beta-glucan. Oat beta-glucan is preferably used. The beta-glucan extracted from the oat bran has no branched chain structure, is different from the multi-fork cluster structure of the yeast beta-glucan, and is more beneficial to skin penetration and absorption. Oat beta-glucan, with multiple skin care benefits: promoting Langerhans cell proliferation, improving skin immunity, relieving inflammation, promoting wound healing, and keeping moisture.
As a preferable technical scheme, the paint also comprises polyalcohol and water. Wherein the polyhydric alcohol comprises, but is not limited to, butanediol, 1, 2-hexanediol, caprylyl glycol, glycerol, 1, 2-pentanediol and 1, 3-propanediol, and the addition amount is 15-150 parts; 20-800 parts of water.
As a preferred technical scheme, the xanthan gum also comprises 0.001-1 part of xanthan gum.
As a preferable technical scheme, the preservative also comprises 0.001-1 part of preservative. The preservative includes, but is not limited to, phenoxyethanol, ethylhexylglycerin.
The invention also provides the application of the anti-allergy and soothing composition in cosmetics, wherein the addition amount of the composition is 0.1-20%.
As a preferred technical solution, the cosmetic includes, but is not limited to, water, milk, cream, essence, and facial mask.
Compared with the prior art, the invention has the beneficial effects that:
(1) the composition provided by the invention has the advantages that through the interaction between the components, namely the synergistic effect, on one hand, the moisture content of the skin is improved, the immunity of the skin is improved, on the other hand, the skin discomfort caused by acute inflammation is relieved, the skin aging acceleration caused by chronic inflammation is reduced, the skin is soft, moist and comfortable, and the effects of well and long-term moisturizing and relieving sensitive skin are achieved.
(2) The evodia rutaecarpa extract is extracted at normal temperature by adopting a high-pressure/complex enzyme extraction method, and the ultrahigh-pressure extraction is carried out, so that the damage to nutrient components is less, and the extraction is rapid; the biological enzymolysis temperature is low, and the content of active effective components is greatly improved.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention. For process parameters or conditions not specifically mentioned, it can be carried out with reference to conventional techniques.
The starting materials used in the present invention are commercially available.
Example 1
The embodiment provides an anti-allergy and soothing composition which comprises the following components in parts by weight: 0.001g of oat beta-glucan, 0.001g of glycerophosphocholine salt, 3g of radix ophiopogonis extract, 3g of twisted cactus stem extract and 3g of sophora flavescens root extract.
Example 2
The embodiment provides an anti-allergy and soothing composition which comprises the following components in parts by weight: 0.5g of oat beta-glucan, 18g of trehalose, 0.05g of glycerophosphocholine, 8g of radix ophiopogonis extract, 8g of prickly pear stem extract, 8g of sophora flavescens root extract and 0.3g of fructus evodiae extract.
The fructus evodiae extract is mainly prepared by the following steps:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: adding 10mL of the extract solution, placing the mixture into a pressure-resistant bag, treating for 3 minutes under certain pressure, and recovering the solution part, wherein the extraction solvent is propylene glycol, and the pressure is 250 Mpa;
s3: taking the solution obtained in the step S2, adding complex enzyme with the weight of 0.4% of the powder, and carrying out enzymolysis for 3h at 40 ℃; the complex enzyme is prepared by mixing cellulase and pectinase in a weight ratio of 2: 1;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: adding 20mL of the extract into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirring, carrying out oscillation reaction for 1-2 h at the temperature of 60 ℃, standing, and recovering an upper phase extract after phase separation;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
Example 3
The embodiment provides an anti-allergy and soothing composition which comprises the following components in parts by weight: 5g of yeast beta-glucan, 0.001g of oat beta-glucan, 10g of trehalose, 0.8g of glycerophosphoinositide choline salt, 5g of radix ophiopogonis extract, 5g of twisted cactus stem extract, 5g of radix sophorae flavescentis extract, 1g of fructus evodiae extract and 0.05g of milfoil extract.
The fructus evodiae extract is mainly prepared by the following steps:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: adding 25mL of the extract solution, placing the mixture into a pressure-resistant bag, treating for 3 minutes under certain pressure, and recovering the solution part, wherein the extraction solvent is propylene glycol, and the pressure is 300 MPA;
s3: taking the solution obtained in the step S2, adding complex enzyme with the weight of 0.7% of the powder, and carrying out enzymolysis for 2h at 40 ℃; the complex enzyme is prepared by mixing cellulase, xylanase and pectinase in a weight ratio of 1:1: 1;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: adding 10mL of the extract into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirring, carrying out oscillation reaction for 1-2 h at the temperature of 50 ℃, standing, and recovering an upper phase extract after phase separation;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
Example 4
The embodiment provides an anti-allergy and soothing composition which comprises the following components in parts by weight: 5g of oat beta-glucan, 12g of trehalose, 0.2g of glycerophosphoinositide choline salt, 2g of radix ophiopogonis extract, 2g of prickly pear stem extract, 2g of radix sophorae flavescentis extract, 2g of fructus evodiae extract, 20g of oat peptide, 35g of butanediol, 5g of glycerol, 10g of 1, 2-pentanediol, 5g of 1, 3-propanediol, 100g of water, 0.01g of ethylhexylglycerol and 0.09g of phenoxyethanol.
The fructus evodiae extract is mainly prepared by the following steps:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: adding 20mL of the extract solution, placing the mixture into a pressure-resistant bag, treating for 3 minutes under certain pressure, and recovering the solution part, wherein the extraction solvent is propylene glycol, and the pressure is 250 MPA;
s3: taking the solution obtained in the step S2, adding complex enzyme with the weight of 0.5% of the powder, and carrying out enzymolysis for 3h at 50 ℃; the complex enzyme is prepared by mixing cellulase, xylanase and glucanase in a weight ratio of 2:1: 1;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: adding 15mL of the extract into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirring, carrying out oscillation reaction for 1-2 h at the temperature of 50 ℃, standing, and recovering an upper phase extract after phase separation;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
Example 5
The embodiment provides an anti-allergy and soothing composition which comprises the following components in parts by weight: 7g of oat beta-glucan, 10g of trehalose, 0.1g of glycerophosphoinositide choline salt, 5g of radix ophiopogonis extract, 3g of prickly pear stem extract, 4g of radix sophorae flavescentis extract, 1g of fructus evodiae extract, 20g of oat peptide, 0.5g of milfoil extract, 1g of caprylyl glycol, 50g of butanediol, 5g of 1, 3-propylene glycol and 0.001g of xanthan gum.
The fructus evodiae extract is mainly prepared by the following steps:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: adding 20mL of the mixture into an extraction solution, placing the mixture into a pressure-resistant bag, treating the mixture for 3 minutes under certain pressure, and recovering a solution part, wherein the extraction solvent is butanediol, and the pressure is 350 MPA;
s3: taking the solution obtained in the step S2, adding complex enzyme with the weight of 0.5% of the powder, and carrying out enzymolysis for 3h at 50 ℃; the complex enzyme is prepared by mixing cellulase, xylanase and glucanase in a weight ratio of 2:1: 1;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: adding 15mL of the extract into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirring, carrying out oscillation reaction for 1-2 h at the temperature of 50 ℃, standing, and recovering an upper phase extract after phase separation;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
Example 6
The embodiment provides an anti-allergy and soothing composition which comprises the following components in parts by weight: 10g of oat beta-glucan, 7g of trehalose, 0.005g of glycerophosphocholine salt, 5g of radix ophiopogonis extract, 5g of prickly pear stem extract, 5g of radix sophorae flavescentis extract, 0.5g of fructus evodiae extract, 10g of oat peptide, 1g of milfoil extract, 200g of water, 5g of caprylyl glycol, 30g of butanediol, 10g of 1, 3-propanediol and 0.01g of xanthan gum.
The fructus evodiae extract is mainly prepared by the following steps:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: adding 20mL of the mixture into an extraction solution, placing the mixture into a pressure-resistant bag, treating the mixture for 3 minutes under certain pressure, and recovering a solution part, wherein the extraction solvent is butanediol, and the pressure is 300 MPA;
s3: taking the solution obtained in the step S2, adding complex enzyme with the weight of 0.5% of the powder, and carrying out enzymolysis for 3h at 50 ℃; the complex enzyme is prepared by mixing cellulase, pectinase, xylanase and glucanase in a weight ratio of 1:2:1: 1;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: adding 15mL of the extract into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirring, carrying out oscillation reaction for 1-2 h at the temperature of 50 ℃, standing, and recovering an upper phase extract after phase separation;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
Comparative example 1
This comparative example provides a composition without oat beta glucan compared to example 1.
Comparative example 2
This comparative example provides a composition without the addition of glycerophosphoinositide choline salt, compared to example 1.
Comparative example 3
This comparative example provides a composition with an addition of 1g of ophiopogon root extract compared to example 1,
comparative example 4
This comparative example provides a composition of 1g of extract of the stem of Opuntia ficus-indica compared to example 1.
Comparative example 5
This comparative example provides a composition of 1g of extract of kuh-seng root compared to example 1.
Efficacy verification test
1. Chick embryo chorioallantoic membrane test
The experimental method comprises the following steps: the negative control sample is sodium chloride solution with mass concentration of 0.9% and is used for washing and negative control after the action of the test object, and the positive control sample is 1% SDS. Taking out the chick embryo from the incubator, placing the chick embryo on a self-made egg rack with the air chamber end upward, adding a small amount of sodium chloride solution on the eggshell membrane after opening the air chamber to moisten the chick embryo, sucking the sodium chloride solution, and carefully removing the inner membrane by using a bent forceps to ensure that the vascular membrane is not damaged. The structure of the vascular system should be observed again at this point and a decision made as to its integrity and suitability for testing. A certain amount of the prepared 0.1-20% composition solution obtained in examples 1-6 is dripped onto the CAM membrane, and the phenomenon of intimal vessels is observed and recorded for 1-5 min.
And (3) testing results: 0.1-20% of the composition solution of the embodiment of the invention is dripped on the branch blood vessel of the chick embryo intima clearly, and the blood vessel after 5min has no phenomena of bleeding, hemolysis, blood coagulation and the like, which shows that the composition of the invention has no irritation to human skin basically and is milder.
2. Evaluation test of efficacy of sensitive skin
Test samples: the compositions provided in examples 1-6 and comparative examples 1-5.
The experimental method comprises the following steps: people (18-45 years old) with sensitive skin or allergic (red and itchy) faces are screened out to be 110 sensitive skin volunteers (11 groups and 10 people in each group), the test is carried out on the 0 th day, the 7 th day and the 14 th day respectively after the composition provided by the embodiment of the invention and the comparative example is applied to the faces of the subjects every day, the skin moisture content and the skin moisture loss are measured by a skin moisture content tester (Corneometer CM825), and the sensitive skin is judged to be relieved according to the disappearance of the red and itchy faces of the subjects. These indices are used to evaluate skin barrier function and the ability of the skin to repair after use of the product.
The test was carried out for 2 weeks, and the moisture content and the moisture loss of the skin were measured before and after the use of the sample, and the red and itchy face of the subject was recorded, and the test results are shown in table 1.
TABLE 1
As can be seen from the data in Table 1, after 2 weeks using the sample, the skin moisture content of the subjects using the compositions of examples 1-6 is obviously increased, the moisture loss is reduced, and the allergy condition is obviously relieved, so that the anti-allergy soothing compositions prepared in examples 1-6 have good functions of repairing the skin barrier and relieving the sensitive skin, and the effect is better than that of comparative examples 1-5.
It should be understood that the above-mentioned embodiments of the present invention are only examples for clearly illustrating the technical solutions of the present invention, and are not intended to limit the specific embodiments of the present invention. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention claims should be included in the protection scope of the present invention claims.
Claims (10)
1. A skin care composition comprising the following active ingredients: beta-glucan, glycerophosphoinositide choline salt, an ophiopogon root extract, a twisted cactus stem extract and a sophora flavescens root extract.
2. The skin care composition according to claim 1, comprising the following ingredients in parts by weight:
0.001-12 parts of beta-glucan;
0.0001-1 part of glycerol phosphoinositide choline salt;
2-10 parts of an ophiopogon root extract;
2-10 parts of a twisted cactus stem extract;
2-10 parts of sophora flavescens root extract.
3. The skin care composition according to claim 1 or 2, further comprising 3-20 parts of trehalose; and/or 0.05-4 parts of fructus evodiae extract.
4. The skin care composition according to claim 3, further comprising 1-40 parts of oat peptide.
5. The skin care composition according to claim 3, further comprising 0.005 to 2 parts of an extract of Achillea millefolium.
6. A skin care composition according to any one of claims 1 to 5 wherein the beta-glucan is one or more of oat beta-glucan, yeast beta-glucan.
7. The skin care composition of claim 3, wherein the evodia rutaecarpa extract is prepared by:
s1: drying and crushing the fructus evodiae to obtain fructus evodiae powder;
s2: and (3) mixing the powder obtained in the step S1 according to the ratio of material to liquid of 1 g: (10-30) mL of the extract solution is added, the mixture is placed in a pressure-resistant bag and treated for 3-5 minutes under certain pressure, and a solution part is recovered, wherein the extraction solvent is one or more of water, propylene glycol and butanediol, and the pressure is 250-350 MPa;
s3: adding complex enzyme with the weight of 0.4-0.7% of the powder into the solution obtained in the step S2, and performing enzymolysis for 2-4h at 40-50 ℃; the complex enzyme is two or more of cellulase, pectinase, glucanase, xylanase and amylase;
s4: taking the supernatant obtained after the enzymolysis reaction in the step S3, inactivating enzyme for 15min under the condition of water bath at 100 ℃, performing suction filtration, collecting filtrate, and concentrating the filtrate under reduced pressure to obtain a paste to obtain a fructus evodiae crude extract;
s5: and (3) mixing the crude extract prepared in the step S4 according to the solid-to-liquid ratio of 1 g: (10-20) mL of the extract is added into an ethanol-ammonium sulfate double aqueous phase extraction system, uniformly stirred, subjected to oscillation reaction for 1-2 hours at the temperature of 50-70 ℃, kept stand, subjected to phase splitting and then recovered into an upper phase extract;
s6: concentrating the upper phase extract liquid in the step S5 and drying in vacuum to obtain the fructus evodiae extract.
8. The skin care composition according to any one of claims 1 to 5, further comprising a polyol and water.
9. Use of the skin care composition according to any one of claims 1 to 8 in cosmetics, wherein the composition is added in an amount of 0.1% to 20%.
10. Use according to claim 9, characterized in that said cosmetic product comprises water, milk, cream, serum, mask.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110216055.6A CN112972354A (en) | 2021-02-26 | 2021-02-26 | Skin care composition and application thereof in cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110216055.6A CN112972354A (en) | 2021-02-26 | 2021-02-26 | Skin care composition and application thereof in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112972354A true CN112972354A (en) | 2021-06-18 |
Family
ID=76350964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110216055.6A Pending CN112972354A (en) | 2021-02-26 | 2021-02-26 | Skin care composition and application thereof in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112972354A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440461A (en) * | 2021-06-23 | 2021-09-28 | 植物医生(广东)生物科技有限公司 | Soothing and allergy-reducing composition and application thereof |
| CN114732777A (en) * | 2022-05-12 | 2022-07-12 | 广州宏众生物科技有限公司 | Composition with moisturizing and relieving effects and preparation method thereof |
| CN115105423A (en) * | 2022-07-18 | 2022-09-27 | 深圳浦瑞健康科技有限公司 | Composition with anti-inflammatory and anti-allergy activity and application thereof |
| CN115737491A (en) * | 2022-03-23 | 2023-03-07 | 北京东方淼森生物科技有限公司 | Plant composition and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105669604A (en) * | 2016-03-09 | 2016-06-15 | 大兴安岭富林山野珍品科技开发有限责任公司 | New method for purifying wild hazel-mushroom taxol through ultrahigh-pressure extraction, biological enzymolysis and countercurrent chromatography |
| CN108853278A (en) * | 2018-07-30 | 2018-11-23 | 深圳市本草王化妆品有限公司 | Dredging collateral and promoting blood circulation qi-regulating is dried easypro bone compositions and preparation method thereof |
| CN110339106A (en) * | 2019-06-26 | 2019-10-18 | 海南智者合实业有限公司 | A kind of multiple-effect facial mask essence |
| CN110386875A (en) * | 2019-06-16 | 2019-10-29 | 山东省中医药研究院 | A method of separating caffeoyl gluconic acid serial position isomers from evodia rutaecarpa |
| CN110448509A (en) * | 2019-09-06 | 2019-11-15 | 奢脉国际化妆品(北京)有限公司 | A kind of polypeptide Essence and preparation method thereof having effects that Shu Min is repaired |
-
2021
- 2021-02-26 CN CN202110216055.6A patent/CN112972354A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105669604A (en) * | 2016-03-09 | 2016-06-15 | 大兴安岭富林山野珍品科技开发有限责任公司 | New method for purifying wild hazel-mushroom taxol through ultrahigh-pressure extraction, biological enzymolysis and countercurrent chromatography |
| CN108853278A (en) * | 2018-07-30 | 2018-11-23 | 深圳市本草王化妆品有限公司 | Dredging collateral and promoting blood circulation qi-regulating is dried easypro bone compositions and preparation method thereof |
| CN110386875A (en) * | 2019-06-16 | 2019-10-29 | 山东省中医药研究院 | A method of separating caffeoyl gluconic acid serial position isomers from evodia rutaecarpa |
| CN110339106A (en) * | 2019-06-26 | 2019-10-18 | 海南智者合实业有限公司 | A kind of multiple-effect facial mask essence |
| CN110448509A (en) * | 2019-09-06 | 2019-11-15 | 奢脉国际化妆品(北京)有限公司 | A kind of polypeptide Essence and preparation method thereof having effects that Shu Min is repaired |
Non-Patent Citations (2)
| Title |
|---|
| 刘建勋: "《中药药理学》", 31 January 2020, 中国协和医科大学出版社 * |
| 广东梵蜜琳生物科技有限公司: "梵蜜琳 臻活凝肌精华液", 《国产非特殊用途化妆品备案电子凭证》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440461A (en) * | 2021-06-23 | 2021-09-28 | 植物医生(广东)生物科技有限公司 | Soothing and allergy-reducing composition and application thereof |
| CN115737491A (en) * | 2022-03-23 | 2023-03-07 | 北京东方淼森生物科技有限公司 | Plant composition and preparation method and application thereof |
| CN115737491B (en) * | 2022-03-23 | 2023-12-26 | 北京东方淼森生物科技有限公司 | Plant composition and preparation method and application thereof |
| CN114732777A (en) * | 2022-05-12 | 2022-07-12 | 广州宏众生物科技有限公司 | Composition with moisturizing and relieving effects and preparation method thereof |
| CN114732777B (en) * | 2022-05-12 | 2023-11-28 | 广州宏众生物科技有限公司 | Composition with moisturizing and soothing effects and preparation method thereof |
| CN115105423A (en) * | 2022-07-18 | 2022-09-27 | 深圳浦瑞健康科技有限公司 | Composition with anti-inflammatory and anti-allergy activity and application thereof |
| CN115105423B (en) * | 2022-07-18 | 2023-12-22 | 深圳浦瑞健康科技有限公司 | Composition with anti-inflammatory and anti-allergic activities and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112972354A (en) | Skin care composition and application thereof in cosmetics | |
| CN108653035B (en) | Whitening and moisturizing small-molecule peptide mask and preparation method thereof | |
| CN110772463B (en) | Eye skin repair composition and preparation method and application thereof | |
| CN108815072B (en) | Fresh plant composition fermented raw pulp with moisturizing and relieving effects and preparation method and application thereof | |
| CN102274141B (en) | Herba selaginellae revival moisturizing cream and preparation method thereof | |
| CN102210643B (en) | Anti-wrinkle cosmetic composition and preparation method thereof | |
| CN110787100A (en) | Anti-allergy skin-soothing essence and preparation method thereof | |
| CN108703931B (en) | Composition with moisturizing effect and preparation method thereof | |
| CN112675122A (en) | Soothing and repairing essence and preparation method thereof | |
| CN113041174B (en) | Oil tea seed oil essence containing hydrolyzed vegetable protein and preparation method and application thereof | |
| CN112999137B (en) | Moisturizing, relieving and repairing cream containing mineral hot spring water and preparation method thereof | |
| CN107648585A (en) | A kind of anti-ageing anti-wrinkle Essence containing white fungus, aurantiamarin and soluble protein | |
| CN111388394A (en) | Biphase freeze-dried powder solvent and preparation method and application thereof | |
| CN110585079A (en) | Radiation-resistant composition containing food-borne peptide and radiation-resistant emulsion thereof | |
| CN110680775A (en) | Pure whitening, moisturizing and hydrating liquid and preparation method thereof | |
| CN115137675A (en) | Compound plant extract with moisturizing effect and application thereof | |
| CN113318062B (en) | Skin barrier repairing composition, skin barrier repairing liquid and preparation method thereof | |
| CN109646359B (en) | Rose-agaric mud membrane paste with effects of cleaning, purifying, maintaining beauty and keeping young and preparation method thereof | |
| CN109453104B (en) | Spot-fading skin-refreshing essence and preparation process thereof | |
| CN113750017A (en) | Method for preparing dendrobium nobile skin care product with whitening effect | |
| CN111803403A (en) | Sandalwood essential oil composition | |
| CN110585107A (en) | Wonderful age essence capable of firming skin, moistening skin, beautifying skin and deeply replenishing water and preparation method thereof | |
| CN112641685A (en) | Moisturizing and circulation promoting essence and preparation method thereof | |
| CN117694549B (en) | Moisturizing, freckle-removing and whitening composition, preparation method and application | |
| CN108159152A (en) | Pure acyl anticancer compound enzyme formula and production process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210618 |